IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen
Authors
Lee, S. M.Schulz, C.
Prabhash, K.
Han, B.
Szczesna, A.
Cortinovis, D. L.
Rittmeyer, A.
Baz, D. V.
Califano, Raffaele
Anh, L. T.
Liu, G.
Cappuzzo, F.
Contreras, J. G. R.
Reck, M.
Hu, Y.
Morris, S.
Hoeglander, E. K.
Connors, M.
Vollan, H. K. M.
Peters, S.
Affiliation
Dept Of Oncology, University College London Hospitals NHS Foundation Trust, UCL Cancer Institute and CRUK Lung Cancer Centre of Excellence, NW1 2PG - London/GBIssue Date
2022
Metadata
Show full item recordCitation
Lee SM, Schulz C, Prabhash K, Han B, Szczesna A, Cortinovis DL, et al. IPSOS: Results from a phase III study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen. Annals of Oncology. 2022 Sep;33(7):S1418-S9. PubMed PMID: WOS:000866211602462.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1089Additional Links
https://dx.doi.org/10.1016/annonc/annonc1089Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1089